Successful induction of molecular remission with single-agent anti-CD33 antibody (gemtuzumab ozogamicin) in chemotherapy-refractory relapse of acute myeloid leukaemia post-BMT.

Swords, R; Hayden, P J; Molloy, K; Lawlor, M; Browne, P V; Murphy, P T

Swords, R; Hayden, P J; Molloy, K; Lawlor, M; Browne, P V; Murphy, P T.

Eur J Haematol ; 73(6): 450-1, 2004 Dec.

Article in En | MEDLINE | ID: mdl-15522070

Subject(s)

Aminoglycosides/therapeutic use; Antibodies, Monoclonal/therapeutic use; Immunization, Passive; Leukemia, Myeloid/therapy; Salvage Therapy; Acute Disease; Adolescent; Antibodies, Monoclonal, Humanized; Antigens, CD/immunology; Antigens, Differentiation, Myelomonocytic/immunology; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Bone Marrow Transplantation; Combined Modality Therapy; Drug Resistance, Neoplasm; Gemtuzumab; Humans; Immunoconjugates/therapeutic use; Leukemia, Myeloid/drug therapy; Male; Remission Induction; Sialic Acid Binding Ig-like Lectin 3; Transplantation, Homologous

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid / Immunization, Passive / Salvage Therapy / Aminoglycosides / Antibodies, Monoclonal Limits: Adolescent / Humans / Male Language: En Journal: Eur J Haematol Year: 2004 Document type: Article

Search on Google

XML

PubMed Links